Charles River Laboratories International CRL
NYSE CRL
$282.06 +8.65 (+3.16%)
As of: Sep 17, 2026 · 3:59 PM EDT

Charles River Laboratories International (CRL) EBITDA Margin Growth (1y) (2010 - 2026)

Analysis

Charles River Laboratories International (CRL) EBITDA Margin Growth (1y) (2010 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (1y) (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn -101.00
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn -38.00
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn -463.00
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn 224.00
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn 4,868.00
6 Evotec SE 574.75 Mn 148.87 Mn - -
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn -14,185.00
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn 108.00
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn -21.83 Mn
10 VivoSim Labs 1.37 Mn 1.37 Mn - -744,940.00
Historic Data

Historic Data

Download Data
DateValue
Jun 27, 2026 224.00
Mar 28, 2026 445.00
Dec 27, 2025 -1,178.00
Sep 27, 2025 169.00
Jun 28, 2025 -508.00
Mar 29, 2025 -487.00
Dec 28, 2024 -2,984.00
Sep 28, 2024 -313.00
Jun 29, 2024 -78.00
Mar 30, 2024 -386.00
Dec 30, 2023 -178.00
Sep 30, 2023 -51.00
Jul 1, 2023 -370.00
Apr 1, 2023 3.00
Dec 31, 2022 -420.00
Sep 24, 2022 -213.00
Jun 25, 2022 422.00
Mar 26, 2022 128.00
Dec 25, 2021 279.00
Sep 25, 2021 -47.00